Deprecated: Function get_magic_quotes_gpc() is deprecated in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 152

Notice: Undefined property: stdClass::$live in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 469

Notice: Undefined property: stdClass::$live in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 474

Notice: Undefined variable: type in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 560

Notice: Undefined variable: sortString in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 563
TWELVE ZERO ZERO

TWELVE ZERO ZERO

Brand Owner Address Description
12 00 MONBO, TAJE C/0: D. Monbo 10451 Mill Run Circle, #400 Owings Mills MD 21117 TWELVE ZERO ZERO; ONE TWO ZERO ZERO;Land motor vehicles, namely, motorcycles, all-terrain vehicles, ATVs, motor scooters, mopeds, motorized bicycles, motor tricycles, all not being toys, quads being four-wheeled motor vehicles and their structural parts therefor; Motorcycles and structural parts therefor; All-terrain four-wheel motorcycles and structural parts therefor; Motorcycles suspension systems and structural parts therefor; Land motor vehicles for use in motorsports, movies, and films; All-terrain vehicles, light utility vehicles being motor vehicles, quad bikes being four-wheeled motor vehicles, all-terrain four-wheel motorcycles, and ATVs for use in movies, films, and videos;The mark was first used in commerce in a different form other than that sought to be registered at least as early as 06/25/2001;The mark was first used anywhere in a different form other than that sought to be registered at least as early as 06/25/2001;
 

Where the owner name is not linked, that owner no longer owns the brand

   
Technical Examples
  1. The present invention is directed to a method to prevent or reduce postoperative corneal subepithelial haze after excimer laser photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK) surgery. According to the method, a therapeutically effective amount of one or more plasminogen activators, most preferably urokinase (uPA), is administered topically to the surface of the affected eye at levels between 0.1 and 2,500 IU/ml, about eight to twelve times on the day of surgery, and four to eight times per day for about the next six to twelve days thereafter. The most preferred therapeutic amount is from about 0.1-1 IU uPA/ml, and also 1-10 IU/ml. Plasminogen activators that can be used in the inventions include urokinase, prourokinase, streptokinase and mutants thereof. The invention also covers topical ophthalmic compositions that include one or more plasminogen activators, most preferably uPA, to prevent or reduce postoperative corneal subepithelial haze.